Features | Partner Sites | Information | LinkXpress
Sign In
GLOBETECH PUBLISHING LLC
Schiller
Ampronix

“Fastener” Molecules Enhance MRI Contrast Agents

By Medimaging International staff writers
Posted on 04 Jun 2014
Image: Dr. Kong and others demonstrated that their fastener molecule readily inserted itself into the membrane of pre-made liposomes. Gadolinium stably associated with the modified nanoparticles in solution, and experiments in animal models showed that these nanoparticles produced clear diagnostic images (Photo courtesy of Janet Sinn-Hanlon, DesignGroup@VetMed, University of Illinois).
Image: Dr. Kong and others demonstrated that their fastener molecule readily inserted itself into the membrane of pre-made liposomes. Gadolinium stably associated with the modified nanoparticles in solution, and experiments in animal models showed that these nanoparticles produced clear diagnostic images (Photo courtesy of Janet Sinn-Hanlon, DesignGroup@VetMed, University of Illinois).
Biomedical scientists have increased the effectiveness of specific contrast agents that are frequently used for imaging blood vessels and internal bleeding by linking them with nanoparticles. The contrast agent being used is packaged inside or bonded to the surface of microscopic particles, which can be designed to target specific parts of the body or prolong the agent’s activity.

When associate professor of chemical and biomolecular engineering Dr. Hyunjoon Kong, graduate student Cartney Smith, and colleagues from the Institute for Genomic Biology, University of Illinois at Urbana-Champaign (USA) set out to improve magnetic resonance imaging (MRI) technology, they turned to current contrast agent technology inside out.

When clinicians perform an MRI scan, they administer a contrast agent: a compound that, when injected into the bloodstream or ingested by the patient just before the MRI, improves structure or organ clarity in the resulting image. One typical class of contrast agent, frequently used for imaging of blood vessels and internal bleeding, contains gadolinium, a rare-earth metal.

Recently, biomedical researchers have discovered ways to increase the effectiveness of certain contrast agents by associating them with nanoparticles. The contrast agent being used is packaged inside or bonded to the surface of microscopic particles, which can be designed to target certain regions of the body or prolong the agent’s activity. They are now examining the multipurpose use of nanoparticles. If particles could be loaded with several types of contrast agents or dyes instead of one, or a contrast agent along with another type of diagnostic aid or a medication, clinicians could more effectively test for and treat disorders, and limit the number of injections received by patients.

Similar to children sharing a new plaything, although, compounds packed together into a nanoparticle cannot always play well together. For instance, contrast agents may bind to other chemicals, reducing their effectiveness. Furthermore, when contrast agents are enclosed inside a nanoparticle, they may not work as well. Efforts to attach agents to the outer surface of nanoparticles by covalent formation are also challenging, as they can negatively affect the nanoparticle activity or the compounds that they carry.

Drs. Kong, Smith and colleagues attacked these challenges by using interactions between naturally occurring biomolecules as a guide. Many types of proteins are strongly attached to cell membranes not by covalent bonds, but by the sum of multiple weaker forces—the attraction of positive and negative charges, and the tendency of nonpolar (oil-like) compounds to seek each other and avoid water.

The group theorized that the same types of forces could be used to attach a contrast agent to the surface of a type of nanoparticle called a liposome, which resembles a little piece of cell membrane in the shape of a tiny bubble. The researchers designed a “fastener” molecule, DTPA-chitosan-g-C18, that is charged, attracting it to the liposome and binding it to the contrast agent gadolinium. A nonpolar region anchors it to the liposome membrane.

In a series of experiments reported October 2014 American Cancer Society’s journal ACS Nano article, Dr. Kong and coworkers demonstrated that their fastener molecule easily inserted itself into the membrane of pre-made liposomes. Gadolinium stably associated with the engineered nanoparticles in solution, and research in animal models revealed that these nanoparticles generated well-defined diagnostic images.

“The strategy works like Velcro on a molecular level to adhere functional units to the outer leaflet of a liposome,” said Dr. Smith, who was first author on the study. “This work represents a new material design strategy that is scalable and easily implemented. The development of improved contrast agents has the potential to directly impact patients’ lives by detecting damaged blood vessels.”

One of the difficulties of working with liposomes is their tendency to degrade inside the body. When the fastener-loaded liposomes degraded, some of the efficacy of the gadolinium was lost. In a second study published April 8, 2014, in the journal Langmuir, Drs. Kong and Smith developed a process for chemically cross-linking the components of the nanoparticle that prolonged the life of the nanoparticles in biologic environments.

Related Links:

Institute for Genomic Biology, University of Illinois at Urbana-Champaign



Channels

Radiography

view channel
Image: Fujifilm\'s Aspire Cristalle (Photo courtesy of Business Wire).

Diagnostic Imaging Solutions Provider Submits Mammography Upgrade for FDA Approval

A leading provider of medical informatics solutions and diagnostic imaging products has submitted the first of several modules of its Digital Breast Tomosynthesis (DBT) upgrade for its mammography system,... Read more

Ultrasound

view channel

New Ultrasound System Enhances Patient Care and User Experience

A new ultrasound system with innovative specialized transducers and improved image quality, intended for general imaging, women’s health, and shared service applications, has been announced. The system features improved accuracy, performance, assessment tools, advanced automation, and an enhanced user experience.... Read more

Nuclear medicine

view channel

Clinical Study Shows Added Value of Amyloid PET Imaging in the Diagnosis and Treatment of Dementia

Early-onset dementia patients could benefit from a new PET imaging agent developed by a major medical imaging vendor. The results of a clinical study showing the effectiveness of the amyloid PET imaging agent were presented at the Alzheimer’s Association International Conference (AAIC 2015) in Washington DC (USA).... Read more

General/Advanced Imaging

view channel
Image: Illustration of a new technique using Optical Coherence Tomography that could help surgeons differentiate a human brain tumor, red, from surrounding noncancerous tissue, green (Photo courtesy of  Carmen Kut, Jordina Rincon-Torroella, Xingde Li and Alfredo Quinones-Hinojosa/Johns Hopkins Medicine).

Imaging Technique Helps Safer and More Effective Removal of Brain Tumors

Researchers at the Johns Hopkins University have demonstrated a new imaging technology that could enable neurosurgeons to better differentiate between healthy and cancerous brain tissue and perform safer... Read more

Imaging IT

view channel
Image: The Arbor Solution M2150 medical workstation with 21.5\

Multifunction Workstation Screen Meets Critical Certification Standards for Medical Environments

A medical imaging equipment vendor has unveiled a new workstation with a 54.61 cm true flat screen designed for operating rooms, clinical stations, and Picture Archiving and Communications Systems (PACS).... Read more

Industry News

view channel

Guerbet Aims for Global Medical Imaging Leadership by Acquisition of Mallinckrodt’s CMDS Business

Guerbet (Paris, France) has announced a definitive agreement for the acquisition of the Contrast Media and Delivery Systems (CMDS) business of pharmaceutical giant Mallinckrodt (Chesterfield, Derbyshire, UK). The acquisition gave Guerbet and the CMDS unit combined pro-forma sales of nearly EUR 800 million in 2014, a... Read more
 
Copyright © 2000-2015 Globetech Media. All rights reserved.